FENNEC PHARMACEUTICALS INC.FENCEarnings & Financial Report
Nasdaq
NextMar 26, 2026
FENC Q3 2025 Key Financial Metrics
Revenue
$12.5M
Gross Profit
N/A
Operating Profit
$-189.0K
Net Profit
$-638.0K
Gross Margin
N/A
Operating Margin
-1.5%
Net Margin
-5.1%
YoY Growth
78.7%
EPS
$-0.02
Financial Flow
FENNEC PHARMACEUTICALS INC. Q3 2025 Financial Summary
FENNEC PHARMACEUTICALS INC. reported revenue of $12.5M for Q3 2025, with a net profit of $-638.0K (-5.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $12.5M |
|---|---|
| Net Profit | $-638.0K |
| Gross Margin | N/A |
| Operating Margin | -1.5% |
| Report Period | Q3 2025 |
FENNEC PHARMACEUTICALS INC. Annual Revenue by Year
FENNEC PHARMACEUTICALS INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $47.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $47.5M |
| 2023 | $21.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $25.4M | $7.3M | $7.0M | $7.9M | $8.8M | $9.7M | $12.5M |
| YoY Growth | N/A | 1413.2% | 118.4% | 7.0% | -18.6% | -65.5% | 32.9% | 78.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.9M | $69.2M | $63.2M | $58.9M | $44.9M | $46.4M | $44.9M | $49.3M |
| Liabilities | $38.5M | $66.2M | $64.5M | $64.1M | $50.8M | $52.3M | $52.3M | $53.8M |
| Equity | $-11.6M | $3.0M | $-1.4M | $-5.2M | $-5.9M | $-5.9M | $-7.5M | $-4.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.9M | $39.0M | $-8.4M | $-2.2M | $-1.5M | $-4.3M | $-3.7M | $1.5M |